RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET@CS, please correct me if I don't recall these details as has been stated.
1) The Keytruda/BCG compound requires many more installations/visits.
2) Keytruda has possible debilitatiing side effects. Do patients get followup after treatment to see if they are reactive to these side effects? Is that a treatment data point ever recorded so those reactions are tracked? Or would that only happen if the UroOncologist reports the adverse reactions after treatment?
3) Is the BCG/Keytruda compound permitted to treat early onset NMIBC, instead of our requirement to meet BCG resistant NMIBC patients? My point is we're only permitted to treat patients with the worst conditions or "last resort" prior to bladder removal. If true how could our trail not be granted BTD/AA/FDA approval?
I love the science but know nothing of the medical treatment and statistics elements.
Thank you to anyone that can provide any details. I would think this would lead to stong conclusions as to whether FDA/HC would consider an early AA and final approval.
Thank you.
Good Luck to All.
Regards, BK